164 related articles for article (PubMed ID: 34992038)
1. Discovery of G2019S-Selective Leucine Rich Repeat Protein Kinase 2 inhibitors with in vivo efficacy.
Leśniak RK; Nichols RJ; Schonemann M; Zhao J; Gajera CR; Fitch WL; Lam G; Nguyen KC; Smith M; Montine TJ
Eur J Med Chem; 2022 Feb; 229():114080. PubMed ID: 34992038
[TBL] [Abstract][Full Text] [Related]
2. Selective Inhibitors of G2019S-LRRK2 Kinase Activity.
Garofalo AW; Bright J; De Lombaert S; Toda AMA; Zobel K; Andreotti D; Beato C; Bernardi S; Budassi F; Caberlotto L; Gao P; Griffante C; Liu X; Mengatto L; Migliore M; Sabbatini FM; Sava A; Serra E; Vincetti P; Zhang M; Carlisle HJ
J Med Chem; 2020 Dec; 63(23):14821-14839. PubMed ID: 33197196
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase Activity.
Scott JD; DeMong DE; Greshock TJ; Basu K; Dai X; Harris J; Hruza A; Li SW; Lin SI; Liu H; Macala MK; Hu Z; Mei H; Zhang H; Walsh P; Poirier M; Shi ZC; Xiao L; Agnihotri G; Baptista MA; Columbus J; Fell MJ; Hyde LA; Kuvelkar R; Lin Y; Mirescu C; Morrow JA; Yin Z; Zhang X; Zhou X; Chang RK; Embrey MW; Sanders JM; Tiscia HE; Drolet RE; Kern JT; Sur SM; Renger JJ; Bilodeau MT; Kennedy ME; Parker EM; Stamford AW; Nargund R; McCauley JA; Miller MW
J Med Chem; 2017 Apr; 60(7):2983-2992. PubMed ID: 28245354
[TBL] [Abstract][Full Text] [Related]
4. The G2019S mutation in LRRK2 imparts resiliency to kinase inhibition.
Kelly K; Wang S; Boddu R; Liu Z; Moukha-Chafiq O; Augelli-Szafran C; West AB
Exp Neurol; 2018 Nov; 309():1-13. PubMed ID: 30048714
[TBL] [Abstract][Full Text] [Related]
5. Targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of Parkinson's disease.
Domingos S; Duarte T; Saraiva L; Guedes RC; Moreira R
Future Med Chem; 2019 Aug; 11(15):1953-1977. PubMed ID: 31517532
[TBL] [Abstract][Full Text] [Related]
6. Discovery of azaspirocyclic 1H-3,4,5-Trisubstitued pyrazoles as novel G2019S-LRRK2 selective kinase inhibitors.
Leśniak RK; Nichols RJ; Schonemann M; Zhao J; Gajera CR; Lam G; Nguyen KC; Langston JW; Smith M; Montine TJ
Eur J Med Chem; 2022 Nov; 242():114693. PubMed ID: 36049274
[TBL] [Abstract][Full Text] [Related]
7. Differential Inhibition of LRRK2 in Parkinson's Disease Patient Blood by a G2019S Selective LRRK2 Inhibitor.
Bright JM; Carlisle HJ; Toda AMA; Murphy M; Molitor TP; Wren P; Andruska KM; Liu E; Barlow C
Mov Disord; 2021 Jun; 36(6):1362-1371. PubMed ID: 33836114
[TBL] [Abstract][Full Text] [Related]
8. Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity.
Nguyen APT; Tsika E; Kelly K; Levine N; Chen X; West AB; Boularand S; Barneoud P; Moore DJ
Proc Natl Acad Sci U S A; 2020 Jul; 117(29):17296-17307. PubMed ID: 32631998
[TBL] [Abstract][Full Text] [Related]
9. Altered Development of Synapse Structure and Function in Striatum Caused by Parkinson's Disease-Linked LRRK2-G2019S Mutation.
Matikainen-Ankney BA; Kezunovic N; Mesias RE; Tian Y; Williams FM; Huntley GW; Benson DL
J Neurosci; 2016 Jul; 36(27):7128-41. PubMed ID: 27383589
[TBL] [Abstract][Full Text] [Related]
10. Preclinical modeling of chronic inhibition of the Parkinson's disease associated kinase LRRK2 reveals altered function of the endolysosomal system in vivo.
Kluss JH; Mazza MC; Li Y; Manzoni C; Lewis PA; Cookson MR; Mamais A
Mol Neurodegener; 2021 Mar; 16(1):17. PubMed ID: 33741046
[TBL] [Abstract][Full Text] [Related]
11. LRRK2 G2019S-induced mitochondrial DNA damage is LRRK2 kinase dependent and inhibition restores mtDNA integrity in Parkinson's disease.
Howlett EH; Jensen N; Belmonte F; Zafar F; Hu X; Kluss J; Schüle B; Kaufman BA; Greenamyre JT; Sanders LH
Hum Mol Genet; 2017 Nov; 26(22):4340-4351. PubMed ID: 28973664
[TBL] [Abstract][Full Text] [Related]
12. Design of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors Using a Crystallographic Surrogate Derived from Checkpoint Kinase 1 (CHK1).
Williamson DS; Smith GP; Acheson-Dossang P; Bedford ST; Chell V; Chen IJ; Daechsel JCA; Daniels Z; David L; Dokurno P; Hentzer M; Herzig MC; Hubbard RE; Moore JD; Murray JB; Newland S; Ray SC; Shaw T; Surgenor AE; Terry L; Thirstrup K; Wang Y; Christensen KV
J Med Chem; 2017 Nov; 60(21):8945-8962. PubMed ID: 29023112
[TBL] [Abstract][Full Text] [Related]
13. LRRK2 kinase inhibitors reduce alpha-synuclein in human neuronal cell lines with the G2019S mutation.
Zhao Y; Keshiya S; Perera G; Schramko L; Halliday GM; Dzamko N
Neurobiol Dis; 2020 Oct; 144():105049. PubMed ID: 32800998
[TBL] [Abstract][Full Text] [Related]
14. Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 - 2011).
Deng X; Choi HG; Buhrlage SJ; Gray NS
Expert Opin Ther Pat; 2012 Dec; 22(12):1415-26. PubMed ID: 23126385
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel indolinone-based, potent, selective and brain penetrant inhibitors of LRRK2.
Troxler T; Greenidge P; Zimmermann K; Desrayaud S; Drückes P; Schweizer T; Stauffer D; Rovelli G; Shimshek DR
Bioorg Med Chem Lett; 2013 Jul; 23(14):4085-90. PubMed ID: 23768909
[TBL] [Abstract][Full Text] [Related]
16. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
[TBL] [Abstract][Full Text] [Related]
17. MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition.
Fell MJ; Mirescu C; Basu K; Cheewatrakoolpong B; DeMong DE; Ellis JM; Hyde LA; Lin Y; Markgraf CG; Mei H; Miller M; Poulet FM; Scott JD; Smith MD; Yin Z; Zhou X; Parker EM; Kennedy ME; Morrow JA
J Pharmacol Exp Ther; 2015 Dec; 355(3):397-409. PubMed ID: 26407721
[TBL] [Abstract][Full Text] [Related]
18. Development and biological evaluation of[
Malik N; Kornelsen R; McCormick S; Colpo N; Merkens H; Bendre S; Benard F; Sossi V; Schirrmacher R; Schaffer P
Eur J Med Chem; 2021 Feb; 211():113005. PubMed ID: 33248850
[TBL] [Abstract][Full Text] [Related]
19. Exploring the functional impact of mutational drift in LRRK2 gene and identification of specific inhibitors for the treatment of Parkinson disease.
Nagarajan N; Chellam J; Kannan RR
J Cell Biochem; 2018 Jun; 119(6):4878-4889. PubMed ID: 29369408
[TBL] [Abstract][Full Text] [Related]
20. Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor.
Henderson JL; Kormos BL; Hayward MM; Coffman KJ; Jasti J; Kurumbail RG; Wager TT; Verhoest PR; Noell GS; Chen Y; Needle E; Berger Z; Steyn SJ; Houle C; Hirst WD; Galatsis P
J Med Chem; 2015 Jan; 58(1):419-32. PubMed ID: 25353650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
